Page last updated: 2024-09-05

erlotinib hydrochloride and Breathlessness

erlotinib hydrochloride has been researched along with Breathlessness in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Ieda, M; Nagashio, K; Sato, K; Tajiri, K	1
Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY	1
Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC	1
Ayoub, J; Bezjak, A; Chan, RT; Clark, G; Cyjon, A; de Albuquerque Ribeiro, R; Fenton, D; Gerogianni, A; Laberge, F; Lago, S; Noble, J; Reck, M; Seymour, L; Shepherd, FA; Trajkovic, A; Tu, D; von Pawel, J; Zukin, M	1

Trials

2 trial(s) available for erlotinib hydrochloride and Breathlessness

Article	Year
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:2 Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy	2013
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24 Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome	2006

Article

Year

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:2

Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy

2013

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome

2006

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Breathlessness

Article	Year
Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer. International heart journal, 2021, Sep-30, Volume: 62, Issue:5 Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Cardiotoxicity; Disease Progression; Dyspnea; Erlotinib Hydrochloride; Female; Follow-Up Studies; Heart Failure; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors	2021
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report. BMC cancer, 2010, Dec-31, Volume: 10 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2010

Article

Year

Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer.

International heart journal, 2021, Sep-30, Volume: 62, Issue:5

Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Cardiotoxicity; Disease Progression; Dyspnea; Erlotinib Hydrochloride; Female; Follow-Up Studies; Heart Failure; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors

2021

Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.

BMC cancer, 2010, Dec-31, Volume: 10

Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2010